EE209 Can the German Efficiency Frontier Approach Support Decision-Making Processes for Pricing New Medicines? An Application to Second-Line Interventions of Transplant-Ineligible Diffuse Large B-Cell Lymphoma
Abstract
Authors
M.S. Kurte A.C. Siefen F. Jakobs B. von Tresckow H.C. Reinhardt F. Kron